Results 161 to 170 of about 2,657,421 (309)

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Molecular targeting: targeting angiogenesis in solid tumors

Annals of Oncology, 2004
J-C, Soria, J, Fayette, J-P, Armand
openaire   +2 more sources

OncoLog: A Report to Physicians

, 1983
Quarterly newsletter from the University of Texas System Cancer Center, M.D.
Eisen, Leslie L., M.D. Anderson Hospital and Tumor Institute   +1 more
core  

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

Correction to: Aptamer combined with fluorescent silica nanoparticles for detection of hepatoma cells

Discover Nano
Zixi Hu, Juntao Tan, Zongqiang Lai, Rong Zheng, Jianhong Zhong, Yiwei Wang, Xiaoxue Li, Nuo Yang, Jieping Li, Wei Yang, Yong Huang, Yongxiang Zhao, Xiaoling Lu   +12 more
doaj   +1 more source

TAMing the tumor: targeting immune inhibitory receptors on tumor-associated macrophages in pediatric brain tumors - an emerging immunotherapy strategy. [PDF]

J Immunother Cancer
Mooij L, Meesters-Ensing JI, Calkoen FG, van der Lugt J, Meyaard L, Nierkens S, Carvalheiro T.   +6 more
europepmc   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

From tumor targeting to tumor accessibility: surface-engineered bacteria as precision living therapeutics for translational medicine. [PDF]

J Hematol Oncol
Qiao L, Wu L, Xiao Y, Qiu J, Qiao X, Dong X, Lei C, Wang W, Zhao Y, Hua Z.   +9 more
europepmc   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Drug targeting and tumor heterogeneity [PDF]

Journal of Controlled Release, 2009
openaire   +2 more sources